Presentation, diagnosis and treatment of angioedema without wheals: A retrospective analysis of a cohort of 1058 patients

Journal of Internal Medicine

Volumn 277, Issue 5, 2015, Pages 585-593

  Mansi, M ^a   Zanichelli, A ^a   Coerezza, A ^a   Suffritti, C ^a   Wu, M A ^a   Vacchini, R ^a   Stieber, C ^b   Cichon, S ^b,c   Cicardi, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bradykinin; C1 inhibitor; FXII mutation; Nonhistaminergic angioedema

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRESH FROZEN PLASMA; ICATIBANT; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1S INHIBITOR;

ACQUIRED ANGIOEDEMA; ADULT; ANGIOEDEMA WITHOUT WHEAL; ANGIONEUROTIC EDEMA; ARTICLE; C1 NHIBITOR DEFICIENCY HEREDITARY ANGIOEDEMA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FACE; FACTOR XII MUTATION HEREDITARY ANGIOEDEME; FEMALE; FOLLOW UP; GASTROINTESTINAL MUCOSA; GENETIC SCREENING; GENOTYPE; HUMAN; LARYNX; LIMB; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MOUTH CAVITY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND DEGREE RELATIVE; TONGUE; ADOLESCENT; AGED; ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; GENETICS; MIDDLE AGED; MUTATION; PEDIGREE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; COMPLEMENT C1 INHIBITOR PROTEIN; FACTOR XII; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84926682022     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12304     Document Type: Article

References (35)

1. Kaplan AP. Angioedema. World Allergy Organ J 2008; 1: 103-13.
2. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-26.
3. Cicardi M, Bellis P, Bertazzoni G et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med 2014; 9: 85-92.
4. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379: 474-81.
5. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-7.
6. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-9.
7. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-104.
8. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol 2010; 6: 14.
9. Roberts JR, Lee JJ, Marthers DA. Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. Am J Cardiol 2012; 109: 774-5.
10. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106: 650-4.
11. Bauer V, Sotnikova R. Nitric oxide-the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010; 29: 319-40.
12. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002; 347: 621-2.
13. Defendi F, Charignon D, Ghannam A et al. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS ONE 2013; 8: e70140.
14. Zingale LC, Beltrami L, Zanichelli A et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065-70.
15. Pappalardo E, Cicardi M, Duponchel C et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147-54.
16. Madsen F, Attermann J, Linneberg A. Epidemiology of non-hereditary angioedema. Acta Derm Venereol 2012; 92: 475-9.
17. Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol 2013; 13: 337-44.
18. Lin RY, Shah SN. Increasing hospitalizations due to angioedema in the United States. Ann Allergy Asthma Immunol 2008; 101: 185-92.
19. Zuraw BL, Bork K, Binkley KE et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012; 33(Suppl. 1): S145-56.
20. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141: 31-5.
21. Binkley KE, Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546-50.
22. Bork K, Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med 2004; 116: 644-5.
23. Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 2009; 20: 325-32.
24. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010; 126: 918-25.
25. Binkley KE. Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol 2010; 6: 16.
26. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010; 6: 15.
27. Geng B, Riedl MA. HAE update: special considerations in the female patient with hereditary angioedema. Allergy Asthma Proc 2013; 34: 13-8.
28. Munch EP, Weeke B. Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years later. Allergy 1985; 40: 92-7.
29. Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010; 65: 793-5.
30. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452-4.
31. Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med 2003; 115: 420-1.
32. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93: 870-6.
33. Colas C, Montoiro R, Fraj J, Garces M, Cubero JL, Caballero T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol 2012; 22: 520-1.
34. Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-7.
35. Cronin JA, Maples KM. Treatment of an acute attack of type III hereditary angioedema with ecallantide. Ann Allergy Asthma Immunol 2012; 108: 61-2.